Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of SLx-4090 in Combination With Metformin in Subjects With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs KD 026 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Surface Logix
- 04 May 2015 Primary endpoint has been met (Reduction in HbA1c) according to Kadmon Media Release.
- 04 May 2015 Results published in the Kadmon Media Release.
- 25 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA 2010).